Olaparib maintenance therapy in patients (pts) with a BRCA1 and/or BRCA2 mutation (BRCAm) and newly diagnosed advanced ovarian cancer (OC): SOLO1 China cohort

被引：0

作者：

Wu, L. ^{[1
]}

Zhu, J. ^{[2
]}

Yin, R. ^{[3
,4
]}

Wu, X. ^{[5
]}

Lou, G. ^{[6
]}

Wang, J. ^{[7
]}

Gao, Y. ^{[8
]}

Kong, B. ^{[9
]}

Lu, X. ^{[10
]}

Zhou, Q. ^{[11
]}

Wang, Y. ^{[12
]}

Chen, Y. ^{[13
]}

Lu, W. ^{[14
]}

Li, W. ^{[15
]}

Cheng, Y. ^{[16
]}

Liu, J. ^{[17
,18
]}

Ma, X. ^{[19
]}

Zhang, J. ^{[19
]}

机构：

[1] Chinese Acad Med Sci, Canc Hosp, Gynecol Oncol, Beijing, Peoples R China

[2] Zhejiang Canc Hosp, Dept Gynecol Oncol, Hangzhou, Zhejiang, Peoples R China

[3] Sichuan Univ, Dept Gynecol & Obstet, Chengdu, Sichuan, Peoples R China

[4] Sichuan Univ, West China Univ Hosp 2, Minist Educ, Key Lab Obstet & Gynecol & Pediat Dis & Birth Def, Chengdu, Sichuan, Peoples R China

[5] Fudan Univ, Obstet & Gynecol Hosp, Dept Gynecol Oncol, Shanghai, Peoples R China

[6] Harbin Med Univ, Canc Hosp, Dept Gynecol & Oncol, Harbin, Heilongjiang, Peoples R China

[7] Hunan Canc Hosp, Dept Gynecol Oncol, Changsha, Hunan, Peoples R China

[8] Beijing Canc Hosp, Dept Gynecol Oncol, Beijing, Peoples R China

[9] Shandong Univ, Qilu Hosp, Dept Obstet & Gynecol, Jinan, Shandong, Peoples R China

[10] Fudan Univ, Dept Gynecol Oncol, Obstet & Gynecol Hosp, Shanghai, Peoples R China

[11] Chongqing Canc Hosp, Chongqing Off Canc Control & Res, Chongqing, Peoples R China

[12] Xian Jiatong Univ, Sch Med, Affiliated Hosp 1, Xian, Shaanxi, Peoples R China

[13] Soochow Univ, Affiliated Hosp 1, Dept Obstet & Gynecol, Suzhou, Peoples R China

[14] Zhejiang Univ, Womens Hosp, Sch Med, Hangzhou, Zhejiang, Peoples R China

[15] First Hosp Jilin Univ, Ctr Oncol, Changchun, Jilin, Peoples R China

[16] Jilin Canc Hosp, Div Thorac Oncol, Changchun, Jilin, Peoples R China

[17] Sun Yat Sen Univ, State Key Lab Oncol South China, Ctr Canc, Guangzhou, Guangdong, Peoples R China

[18] Sun Yat Sen Univ, Dept Gynecol Oncol, Ctr Canc, Guangzhou, Guangdong, Peoples R China

[19] AstraZeneca, Clin Dev, Shanghai, Peoples R China

来源：

ANNALS OF ONCOLOGY | 2019年 / 30卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

230P

引用

页数：1

共 50 条

[31] BRCA1 and BRCA2 Mutations in Ovarian Cancer
Buerkle, Bernd
Tempfer, Clemens
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2012, 307 (04): : 359 - 359
[32] Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
Kaufman, Bella
Shapira-Frommer, Ronnie
Schmutzler, Rita K.
Audeh, M. William
Friedlander, Michael
Balmana, Judith
Mitchell, Gillian
Fried, Georgeta
Stemmer, Salomon M.
Hubert, Ayala
Rosengarten, Ora
Steiner, Mariana
Loman, Niklas
Bowen, Karin
Fielding, Anitra
Domchek, Susan M.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03) : 244 - 250
[33] Olaparib for the treatment of relapsed ovarian cancer with a BRCA1/2 mutation
Stewart, James
George, Angela
Banerjee, Susana
EXPERT REVIEW OF ANTICANCER THERAPY, 2018, 18 (10) : 947 - 958
[34] Exploring the impact of BRCA1 and BRCA2 mutation type and location on Olaparib maintenance therapy in platinum-sensitive relapsed ovarian Cancer patients: A single center report
Skof, Erik
Stegel, Vida
Dragos, Vita Setrajcic
Blatnik, Ana
Gregoric, Brigita
Skerl, Petra
Klancar, Gasper
Klasinc, Anja Zagozen
Bombac, Alenka
Kraje, Mateja
Novakovic, Srdjan
GYNECOLOGIC ONCOLOGY, 2024, 190 : 104 - 112
[35] Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis
Poveda, A.
Lheureux, S.
Colombo, N.
Cibula, D.
Lindemann, K.
Weberpals, J.
Bjurberg, M.
Oaknin, A.
Sikorska, M.
Gonzalez-Martin, A.
Madry, R.
Perez, M. J. Rubio
Ledermann, J.
Davidson, R.
Blakeley, C.
Bennett, J.
Barnicle, A.
Skof, E.
GYNECOLOGIC ONCOLOGY, 2022, 164 (03) : 498 - 504
[36] Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers
Ramus, Susan J.
Antoniou, Antonis C.
Kuchenbaecker, Karoline B.
Soucy, Penny
Beesley, Jonathan
Chen, Xiaoqing
McGuffog, Lesley
Sinilnikova, Olga M.
Healey, Sue
Barrowdale, Daniel
Lee, Andrew
Thomassen, Mads
HUMAN MUTATION, 2012, 33 (04) : 690 - 702
[37] Cost-effectiveness of olaparib as a maintenance treatment for women with newly diagnosed advanced ovarian cancer and BRCA1/2 mutations in the United States
Muston, Dominic
Hettle, Robert
Monberg, Matthew
McLaurin, Kimmie K.
Gao, Wei
Swallow, Elyse
Zhang, Su
Kalemaj, Iden
Signorovitch, James
Moore, Kathleen
GYNECOLOGIC ONCOLOGY, 2020, 159 (02) : 491 - 497
[38] Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial
Friedlander, Michael
Moore, Kathleen N.
Colombo, Nicoletta
Scambia, Giovanni
Kim, Byoung-Gie
Oaknin, Ana
Lisyanskaya, Alla
Sonke, Gabe S.
Gourley, Charlie
Banerjee, Susana
Oza, Amit
Gonzalez-Martin, Antonio
Aghajanian, Carol
Bradley, William H.
Liu, Joyce
Mathews, Cara
Selle, Frederic
Lortholary, Alain
Lowe, Elizabeth S.
Hettle, Robert
Flood, Emuella
Parkhomenko, Elena
DiSilvestro, Paul
LANCET ONCOLOGY, 2021, 22 (05): : 632 - 642
[39] Modifiers of breast and ovarian cancer risks for BRCA1 and BRCA2 mutation carriers
Milne, Roger L.
Antoniou, Antonis C.
ENDOCRINE-RELATED CANCER, 2016, 23 (10) : T69 - T84
[40] Weight gain and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers
Kim, Shana
Lubinski, Jan
Huzarski, Tomasz
Moller, Pal
Armel, Susan
Karlan, Beth
Senter, Leigha
Eisen, Andrea
Foulkes, William
Singer, Christian
Tung, Nadine
Bordeleau, Louise
Neuhausen, Susan
Olopade, Olufunmilayo
Eng, Charis
Weitzel, Jeffrey
Fruscio, Robert
Narod, Steven
Kotsopoulos, Joanne
MOLECULAR GENETICS AND METABOLISM, 2021, 132 : S357 - S358

← 1 2 3 4 5 →